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Abstract
 
Activation of CD4
 
 
 
 T cells is governed by interplay between stimulatory and inhibitory recep-
tors; predominance of stimulatory signals favors autoimmune reactions. In patients with rheu-
matoid arthritis, expression of the critical costimulatory molecule, CD28, is frequently lost. In-
stead, CD4
 
 
 
CD28
 
null
 
 T cells express killer immunoglobulin-like receptors (KIRs) with a
preferential expression of the stimulatory receptor, CD158j. The frequency of CD4
 
 
 
CD28
 
null
 
T cells in rheumatoid arthritis (RA) correlates with the risk for more severe disease. Moreover,
the 
 
KIR2DS2
 
 gene, which encodes for CD158j, is a genetic risk factor for rheumatoid vasculi-
tis. CD158j signals through the adaptor molecule, KARAP/DAP12, to positively regulate cy-
totoxic activity in NK cells. However, the majority of CD4
 
 
 
CD28
 
null
 
 T cell clones lacked the
expression of KARAP/DAP12. Despite the absence of KARAP/DAP12, CD158j was func-
tional and augmented interferon-
 
 
 
 production after T cell receptor stimulation. Cross-linking
of CD158j resulted in selective phosphorylation of c-Jun NH
 
2
 
-terminal protein kinase (JNK)
and its upstream kinase, MKK4 that led to the expression of ATF-2 and c-Jun, all in the ab-
sence of extracellular signal–regulated kinase (ERK)1/2 phosphorylation. Mutation of the
lysine residue within the transmembrane domain of CD158j abolished JNK activation, suggest-
ing that an alternate adaptor molecule was being used. CD4
 
 
 
CD28
 
null
 
 T cells expressed DAP10
and inhibition of phosphatidylinositol 3-kinase, which acts downstream of DAP10, inhibited
JNK activation; however, no interaction of DAP10 with CD158j could be detected. Our data
suggest that CD158j in T cells functions as a costimulatory molecule through the JNK pathway
independent of KARAP/DAP12 and DAP10. Costimulation by CD158j may contribute to
the autoreactivity of CD4
 
 
 
CD28
 
null
 
 T cells in RA.
Key words: autoimmunity • pathogenesis • rheumatoid arthritis • costimulation • killer 
immunoglobulin-like
 
Introduction
 
The killer immunoglobulin-like receptors (KIRs)
 
*
 
 com-
prise a multigene family of receptors that are primarily ex-
pressed on NK cells. In humans, the KIR family is com-
posed of 12 receptors, each of which recognizes specific
MHC class I alleles. Functionally, the members of the KIR
family can be either inhibitory or stimulatory. Because both
inhibitory and stimulatory KIRs share similar extracellular
domains, it is believed that both are capable of binding the
same MHC class I alleles, although with differing affinities
(1). This led to the hypothesis that the balance between
these two classes of receptors regulates NK cell function.
Inhibitory KIRs possess long cytoplasmic tails that con-
tain immunoreceptor tyrosine inhibitory motifs (ITIMs).
Upon binding the appropriate MHC class I molecule, the
inhibitory receptors activate the phosphatase, SHP-1 (2, 3).
This phosphatase dephosphorylates important molecules in
the signaling cascade of stimulatory receptors, such as
CD16, resulting in inhibition of NK cell cytotoxicity (3,
4). This observation supports the missing-self hypothesis,
which suggests that the function of inhibitory KIRs is to
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Fax: 507-284-5045; E-mail: goronzy.jorg@mayo.edu
 
*
 
Abbreviations used in this paper:
 
 ACS, acute coronary syndromes;
 
 
 
ERK,
extracellular signal–regulated kinase; JNK, c-Jun NH
 
2
 
-terminal kinase;
KIR, killer immunoglobulin-like receptor; RA, rheumatoid arthritis.T
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recognize self-MHC class I molecules and prevent self-
directed NK cell cytotoxicity (5).
In contrast to inhibitory KIRs, stimulatory receptors do
not possess a cytoplasmic tail that contains ITIMs, making
these receptors unable to activate protein tyrosine phos-
phatases. In fact, the cytoplasmic tail of stimulatory KIRs
does not contain any known signaling motifs and requires
an adaptor molecule, KARAP/DAP12, to initiate the sig-
naling cascade (6–8). Signaling through KARAP/DAP12
leads to activation of members of the Syk family of protein
tyrosine kinases resulting in extracellular signal–regulated
kinase (ERK) activation, calcium mobilization, and NK
cell cytotoxicity.
In addition to NK cells, T cell subsets express members
of the KIR family. In healthy individuals, the majority of
KIR expression on T cells is limited to CD8
 
 
 
 T cells.
CD8
 
 
 
 T cells that express KIRs are oligoclonally expanded
and possess the memory phenotype, CD44
 
 
 
CD57
 
 
 
CD45RO
 
 
 
CD28
 
null
 
. It has been proposed that KIR ex-
pression on T cells occurs after chronic, antigen-driven
stimulation (9).
In contrast to healthy individuals, patients with rheuma-
toid arthritis (RA) or acute coronary syndromes (ACS) of-
ten possess subpopulations of CD4
 
 
 
 T cells that express
KIRs (10, 11). CD4
 
 
 
KIR
 
 
 
 T cells are clonally expanded
and have lost expression of CD28, suggesting that these
cells have undergone chronic stimulation (12). The expan-
sion of CD4
 
 
 
CD28
 
null
 
 T cells is associated with increased
disease severity in RA (13) and plaque instability in patients
with ACS (14). Of the known members of the KIR family,
the 
 
KIR2DS2
 
 gene, which encodes the CD158j molecule,
is the most frequently expressed KIR on CD4
 
 
 
CD28
 
null
 
 T
cells from patients with RA. Individuals carrying the
 
KIR2DS2
 
 gene are at greater risk of developing RA-asso-
ciated vasculitis, suggesting that CD158j plays a role in the
disease pathogenesis (15).
Because CD158j is a stimulatory receptor on NK cells,
we hypothesized that this molecule functions as a stimula-
tory molecule on CD4
 
 
 
 T cells that have lost CD28 ex-
pression. However, most CD4
 
 
 
 T cells do not express
KARAP/DAP12 and CD158j stimulation in T cells does
not induce activation of the signaling cascade seen in NK
cells. Here, we demonstrate that CD158j selectively acti-
vates the c-Jun NH
 
2
 
-terminal kinase (JNK) signaling path-
way independent of the adaptor molecule, KARAP/
DAP12. Activation of this pathway up-regulates IFN-
 
 
 
 ex-
pression after suboptimal TCR stimulation. We conclude
that CD158j induces inflammation in RA and ACS by reg-
ulating the effector functions of CD4
 
 
 
CD28
 
null
 
 T cells
through the JNK pathway.
 
Materials and Methods
 
Cloning of CD4
 
 
 
CD28
 
null
 
 T Cells.
 
The protocol was ap-
proved by the Mayo Clinic Institutional Review Board and all
patients gave written, informed consent. Peripheral blood
mononuclear cells (PBMCs) from patients with RA were iso-
lated using Ficoll-Hypaque (Amersham Biosciences) and were
 
sorted for CD4
 
 
 
CD28
 
null
 
 T cells by FACS
 
®
 
 using anti-CD4
 
FITC
 
and anti-CD28
 
PE
 
 mAbs (Becton Dickinson). Sorted cells were
cloned using limiting dilution. Clones were maintained on
1.0 
 
 
 
 10
 
6
 
 irradiated heterologous PBMCs/ml, 2.0 
 
 
 
 10
 
5
 
 ir-
radiated Epstein Barr virus–transformed B cells/ml, 30 ng/ml
anti-CD3 mAb (OKT3, CRL 8001; American Type Culture
Collection), and 50 U/ml recombinant human IL-2 (Proleukin;
Chiron Corp.). Established T cell clones were characterized for
the expression of CD28 and CD158b/j by flow cytometry using
anti-CD28
 
FITC
 
 (Becton Dickinson) and anti-CD158b/j
 
PE
 
 mAbs
(GL183; Beckman Coulter).
 
Reverse Transcriptase PCR.
 
For all reverse transcriptase (RT)-
PCR experiments, total RNA was extracted using TRIzol re-
agent (Invitrogen/Life Technologies). cDNA was synthesized us-
ing an oligo-dT primer and AMV reverse transcriptase (Roche
Molecular Diagnostics). CD4
 
 
 
CD28
 
null
 
CD158b/j
 
 
 
 clones were
analyzed for the expression of KIR2DS2 (CD158j), KIR2DL2
(CD158b1), and KIR2DL3 (CD158b2) transcripts using recep-
tor-specific PCR primers described by Uhrberg (16). The
CD158 nomenclature for the cell surface molecules and KIR no-
menclature for the corresponding genes were used as suggested
by the 7th Human Leukocyte Differentiation Antigens Work-
shop (17). CD4
 
 
 
CD28
 
null
 
CD158j
 
 
 
 T cell clones were character-
ized for the expression of KARAP/DAP12 transcript using the
primers 5
 
 
 
-CAGTTGCTCTACGGTGAGC-3
 
 
 
 and 5
 
 
 
-TGT-
GTGTTGAGGTCGCTG-3
 
 
 
. For each RT-PCR analysis,
 
 
 
-actin transcript, amplified by the primers 5
 
 
 
-ATGGCCACG-
GCTGCTTCCAGC-3
 
 
 
 and 5
 
 
 
-CAGGAGGAGCAATGATC-
TTGAT-3
 
 
 
, was used as a control.
 
IFN-
 
 
 
 Analysis.
 
IFN-
 
 
 
 expression was analyzed by real-time,
quantitative PCR and ELISA. For the real-time PCR analysis,
resting CD4
 
 
 
CD28
 
null
 
CD158b/j
 
 
 
 T cell clones were stimulated
with immobilized mouse IgG (ICN Biomedicals), anti-CD3 mAb
(OKT3), anti-CD158b/j mAb (GL183), anti-CD3 and anti-
CD158b/j mAbs, or anti-CD3 and anti-MHC class I (
 
 
 
2-micro-
globulin; L368, HB149; American Type Culture Collection)
mAbs. After 4 h, the cells were harvested, total RNA was ex-
tracted, and cDNA was synthesized. The number of IFN-
 
 
 
 tran-
scripts was determined by real-time, quantitative PCR (LightCy-
cler; Roche Molecular Diagnostics). Primers used for the
amplification were 5
 
 
 
-ACCTTAAGAAATATTTTAATGC-3
 
 
 
and 5
 
 
 
-ACCGAATAATTAGTCAGCTT-3
 
 
 
. For quantification
of protein production, cell supernatants were harvested after 20 h
and IFN-
 
 
 
 was determined by ELISA (Biosource International)
according to the manufacturer’s instructions.
 
PathwayFinder cDNA Array.
 
A resting CD4
 
 
 
CD28
 
null
 
CD158b/j
 
 
 
 T cell clone was treated with either mouse IgG or
anti-CD158b/j mAb and cross-linked with rabbit anti–mouse
IgG polyclonal Ab (ICN Biomedicals). After 4 h, total RNA was
harvested. cDNA was synthesized and used to probe the Path-
wayFinder cDNA Array (SuperArray) according to the manufac-
turer’s instructions.
 
Vaccinia Virus Infection.
 
Jurkat T cells were infected for 18 h
at a ratio of 10:1 (viral PFU:T cell ratio) with either wild-type
(WR) vaccinia virus or recombinant vaccinia virus containing
KIR2DS2 (CD158j) cDNA (both provided by Dr. Paul Leibson,
Mayo Clinic). Cell surface expression of CD158j was confirmed
by flow cytometry.
 
Subcloning, Site-directed Mutagenesis, and Transient Transfection.
 
CDNA for CD158j was amplified using the primers 5
 
 
 
-
TTACGGCGGCCGCATGTCGCTCATGGTCGTC-3
 
 
 
 and
5
 
 
 
-CCGGCTCTAGATTATGCGTATGACACCTCCTG-3
 
 
 
.
The amplified product was digested with Not and XbaI andT
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cloned into the mammalian expression vector pcDNA3.1. A mu-
tant of CD158j was constructed in which lysine 233 was changed
to isoleucine (K233I) according to a previously published proto-
col (18). Briefly, cDNA for CD158j was amplified in two pieces
using the primers 5
 
 
 
-TTACGGCGGCCGCATGTCGCT-
CATGGTCGTC-3
 
 
 
/5
 
 
 
-GAAAGGGATGATGAC- CACT-
GAG-3
 
 
 
 and 5
 
 
 
-CTCAGTGGTCATCATCCCTTTC-3
 
 
 
/5
 
 
 
-
CCGGCTCTAGATTATGCGTATGACACCTCCTG-3
 
 
 
. After
purification, the two PCR products were mixed and amplified as
the full-length cDNA for CD158jK233I. This cDNA was di-
gested with NotI and XbaI and cloned into the mammalian ex-
pression vector pcDNA3.1. The mutation was confirmed by se-
quencing.
Both plasmid constructs were purified using the EndoFree
Plasmid Giga Kit (QIAGEN) and ethanol precipitated. To induce
expression, Jurkat T cells were transiently transfected with these
constructs by electroporation. Cell-surface expression was con-
firmed by flow cytometry. Cells were used for subsequent exper-
iments 48 h after transfection.
 
Cell Stimulation.
 
Resting CD4
 
 
 
CD28
 
null
 
CD158b/j
 
 
 
 T cell
clones or transfected Jurkat T cells were treated with mouse IgG,
anti-CD3, anti-CD158b/j, or anti-CD3 and anti-CD158b/j
mAbs and then cross-linked with rabbit anti–mouse IgG Ab. For
the experiments in which protein phosphorylation was examined,
cells were stimulated for 20 min; for the experiments in which
protein expression was examined, cells were stimulated for 2 h.
For inhibition experiments, cells were treated with 2.0 
 
 
 
M wort-
mannin for 1 h before stimulation. Cells were harvested immedi-
ately after stimulation and were lysed.
 
Western Blots.
 
Between 5 
 
 
 
 10
 
6
 
 and 10 
 
 
 
 10
 
6
 
 cells/sample
were harvested for protein extraction. Samples were incubated on
ice in 50 mM TrisCl (pH 7.6), 150 mM NaCl, 1.0% Triton X-
100, 0.5 mM PMSF, 5.0 
 
 
 
g/ml aprotinin, 10.0  g/ml leupeptin,
1.0 mM orthovanadate. Clarified cell lysates were collected after
centrifugation at 10,000 g for 10 min. The amount of total pro-
tein in each sample was quantified with the Protein Assay Kit II
(BioRad Laboratories). Lysates were analyzed by SDS-PAGE and
transferred onto a nitrocellulose membrane. For the character-
ization of KARAP/DAP12 expression in CD4  CD28null T cell
clones, membranes were blotted in series with specific Abs against
KARAP/DAP12 (provided by Dr. Paul Leibson, Mayo Clinic)
and  -actin (Sigma-Aldrich). For clones that were stimulated be-
fore lysis, the membranes were blotted in series with specific Abs
against phospho-JNK and JNK (both Cell Signaling Technology)
or   -actin (Sigma-Aldrich), phospho-ERK1/2 and ERK1/2,
phospho-MKK4 and MKK4, or c-Jun, ATF-2 (all Cell Signal-
ing Technology), and  -actin (Sigma-Aldrich). Blots were de-
veloped using horseradish peroxidase-conjugated goat anti–rab-
bit IgG or horseradish peroxidase–conjugated rabbit anti–mouse
IgG Abs (both Cell Signaling Technology) and the SuperSignal
West Pico Chemiluminescent Detection System (Pierce Chemi-
cal Co.).
Immunoprecipitation. RBL cells, CD158j  RBL cells, or
CD158j KARAP/DAP12  RBL cells (19) were washed with
1  PBS, 1.0 mM MgCl2, and 1.0 mM CaCl2 and then biotin-
ylated using 1.0 mg/ml sulfo-NHS-LC-biotin (Pierce Chemical
Co.) for 10 min at room temperature. Cells were washed with
1  PBS, 0.1 M Tris, and 0.1 M glycine; 25   106 cells/ml were
lysed in 1.0% digitonin, 0.12% Triton X-100, 150 mM NaCl,
and 20 mM triethanolamine, pH 7.8. Lysates were precleared
with protein G-Sepharose beads (Amersham Biosciences), fol-
lowed by addition of anti-DAP10 or isotype control Abs conju-
gated to protein G-Sepharose beads. Samples were incubated
overnight at 4 C. Immunoprecipitated samples were separated by
SDS-PAGE (15%) and transferred to nitrocellulose membranes.
Blots were developed using horseradish peroxidase–conjugated
streptavidin and the ECL Plus (Amersham Biosciences).
Jurkat T cells were lysed in 50 mM Tris buffer (pH 8.0), 150
mM NaCl, 1.0% NP-40, 1.0 mM EDTA, 1.0 mM PMSF, 10.0
 g/ml aprotinin, and 10.0  g/ml leupeptin. Lysates were pre-
cleared with protein G-Sepharose beads, followed by addition of
anti-DAP10 or anti-KARAP/DAP12 Abs conjugated to protein
G-Sepharose beads. Samples were incubated overnight at 4 C.
Immunoprecipitated samples were separated by SDS-PAGE
(15%) and transferred to nitrocellulose membranes. Blots were
developed using horseradish peroxidase-conjugated streptavidin
and the ECL Plus.
Results
Characterization of CD4 CD28nullCD158b/j  T Cell
Clones. PBMCs were obtained from patients with RA,
and CD4 CD28null T cells were sorted by FACS®. After
limiting dilution cloning, individual clones were character-
ized for the cell surface expression of CD158b/j. Within a
panel of randomly selected clones,  35% of the clones ex-
pressed CD158b/j on the cell surface. Representative
clones are shown in Fig. 1 A. Each of these clones ex-
pressed CD158b/j at levels similar to those previously ob-
served for NK cells.
Within the KIR family there are three receptors that,
due to similarities in the extracellular domains, are recog-
nized by the antibody, GL183. These receptors are
the stimulatory CD158j (KIR2DS2) and the inhibitory
CD158b1 (KIR2DL2) and CD158b2 (KIR2DL3; refer-
ence 17). Therefore, it was not possible to determine by
flow cytometry if a particular clone expressed one receptor
or a mixture of receptors. CD4 CD28nullCD158b/j  T
cell clones were analyzed by RT-PCR with KIR-specific
primers. The majority of the selected clones, including
those shown in Fig. 1 A, expressed transcripts for CD158j
and CD158b1; mRNA for CD158b2 was not detected
(unpublished data).
In NK cells, the stimulatory CD158j uses the adaptor
molecule, KARAP/DAP12, to activate members of the Syk
family of protein tyrosine kinases. However, the majority of
CD4  T cells, including Jurkat T cells, do not express
KARAP/DAP12 (8). CD4 CD28nullCD158b/j  T cell
clones were analyzed for expression of the KARAP/DAP12
transcript and protein (Fig. 1, B and C). Neither KARAP/
DAP12 transcript nor protein could be detected in any of
the clones included in this study or in Jurkat T cells.
CD158b/j Augments IFN-  Expression Induced by Subopti-
mal TCR Stimulation. To determine if CD158j could
function as a costimulatory molecule despite the lack of
KARAP/DAP12, we stimulated CD4 CD28nullCD158b/j 
T cell clones with anti-CD3 and anti-CD158b/j mAbs and
analyzed the expression of IFN- . A representative experi-
ment using real-time PCR to quantify IFN-  transcripts is
shown in Fig. 2 A. Stimulation with high doses of anti-CD3
mAb resulted in a large increase in IFN-  transcript produc-
tion when compared with the control mAb. This level ofT
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induction was not observed if the cells were stimulated with
either suboptimal concentrations of anti-CD3 mAb or opti-
mal concentrations of anti-CD158b/j mAb. However,
when the cells were costimulated with suboptimal concen-
trations of anti-CD3 and optimal concentrations of anti-
CD158b/j mAbs, the increase in IFN-  production was es-
sentially equivalent to the increase observed with the opti-
mal dose of anti-CD3 mAb alone. Stimulation of the cells
with anti-CD3 mAb and a control mAb, anti-MHC class I,
did not enhance IFN-  expression, indicating that the co-
stimulation was a specific function of CD158j. In Fig. 2 B,
IFN-  production was analyzed by ELISA after stimulation
of CD4 CD28nullCD158b/j  T cell clones. As in Fig. 2 A,
stimulation through either the TCR or CD158b/j alone re-
sulted in modest increases in IFN-  expression. However,
costimulation through both receptors resulted in approxi-
mately a threefold increase in IFN-  expression over either
individual receptor stimulation. These data demonstrate
that, in CD4 CD28null T cells, CD158b/j functions as a co-
stimulatory receptor in the absence of KARAP/DAP12.
CD158j Stimulation Results in Increased Transcription of
ATF-2. To identify the signaling pathway used by
CD158b/j in CD4 CD28null T cells, we used cDNA array
technology. The PathwayFinder cDNA Array is a mem-
brane that has been spotted with 23 different cDNAs, each
of which is known to be up-regulated by a specific sig-
naling pathway (Fig. 3 A). After stimulation of a CD4 
CD28nullCD158b/j  T cell clone with either mouse IgG or
anti-CD158b/j mAb, total RNA was harvested and used to
probe the PathwayFinder cDNA Array. In comparison
with the control mAb, stimulation through CD158b/j led
to an increase in transcripts for ATF-2 (positions 1A and
1B) and HSP27 (positions 4C and 4D; Fig. 3 B). The
 -actin and GAPDH controls (positions 3G through 8G,
respectively) indicated that the amount of RNA used for
each membrane was equivalent. The transcription of ATF-2
and HSP27 are regulated by the JNK signaling cascade (20,
21). Other pathways represented on the cDNA array, in-
cluding the NF- B, ERK, and p53 pathways, were not
up-regulated after CD158b/j stimulation, suggesting that
the activation was specific for the JNK pathway.
Activation of CD158b/j Leads to Phosphorylation of JNK but
Not ERK. Activation of the JNK signaling cascade in-
volves phosphorylation of several tyrosine kinases, which in
turn phosphorylate MKK4 on serine and threonine resi-
Figure 1. CD4 CD28null T cell clones express CD158b/j, but do not
express KARAP/DAP12. CD4 CD28null T cells were sorted from pa-
tients with RA, and clones were established by limiting dilution. Clones
were analyzed by flow cytometry for expression of CD28 and CD158b/j.
Four representative clones (#1 through #4) are shown. All clones ex-
pressed CD4 (unpublished data; A). RT-PCR was used to amplify tran-
scripts for KARAP/DAP12 and  -actin from PBMCs (lane 1), Jurkat T
cells (lane 2), and CD4 CD28null T cell clones #1–#4 (lanes 3–6, respec-
tively). cDNA was omitted for the negative control (lane 7) (B). Western
blotting was used to detect KARAP/DAP12 and  -actin protein (bottom
panels) in Jurkat T cells (lane 1), Jurkat T cells transfected with KARAP/
DAP12  vaccinia virus (lane 2), and CD4 CD28null T cell clones (lanes
3–7) (C).
Figure 2. CD158b/j costimulates expression of IFN-   in CD4 
CD28null T cells. CD4 CD28nullCD158b/j  T cell clones were stimu-
lated using immobilized mouse IgG and anti-CD3 mAb alone or in com-
bination with anti-CD158b/j mAb (shown as  g/ml). The number of
IFN-  transcripts was quantified using real-time PCR. Anti-MHC mAb
is included as a negative control (A). Cells were stimulated as above and
IFN-  cytokine production was quantified by ELISA (B).T
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dues. These kinases phosphorylate JNK on tyrosine, serine,
and threonine residues. To confirm the results obtained
with the PathwayFinder cDNA Array, we analyzed the in-
duction of JNK phosphorylation after CD158b/j stimula-
tion. CD4 CD28nullCD158b/j  T cell clones were stimu-
lated with mouse IgG, anti-CD3 mAb, anti-CD158b/j
mAb, or a combination of anti-CD3 and anti-CD158b/j
mAbs. The cell lysates were then analyzed by Western blot
for phosphorylated and total cellular JNK (Fig. 4 A). In all
of the clones analyzed, stimulation with anti-CD158b/j
mAb, either alone or in combination with suboptimal con-
centrations of anti-CD3 mAb, resulted in phosphorylation
of JNK, even in clone #4 that did not phosphorylate JNK
upon CD3 stimulation. Thus, in the CD4 CD28null T
cells, stimulation through CD158b/j led to phosphoryla-
tion of JNK and activation of the JNK pathway.
Results from the PathwayFinder cDNA array suggested
that the JNK pathway was specifically activated after
CD158b/j stimulation and that there was no activation of
the mitogenic ERK pathway. In contrast, CD158j stimula-
tion in NK cells, signaling through KARAP/DAP12, leads
to ERK phosphorylation. Three CD4 CD28nullCD158b/j 
T cell clones were stimulated as previously described and
then analyzed for ERK phosphorylation (Fig. 4 B). Each of
the three clones induced ERK phosphorylation after either
optimal or suboptimal TCR stimulation. In contrast, stim-
ulation through CD158b/j in two of the three clones did
not result in ERK phosphorylation. A third clone did dis-
play some ERK phosphorylation after CD158b/j activa-
tion, although it was minimal in comparison with the level
of ERK phosphorylation detected after TCR stimulation.
In summary, this data suggests that, in the absence of
KARAP/DAP12, CD158b/j specifically uses the JNK cas-
cade as its primary signaling pathway.
Activation of CD158b/j Leads to Phosphorylation of
MKK4. To further characterize the signaling pathway
used by CD158b/j in CD4 CD28null T cells, we analyzed
the activation of the kinase MKK4 directly upstream of
JNK. Several CD4 CD28nullCD158b/j  T cell clones
were stimulated as described previously. The cell lysates
were then analyzed by Western blot for the phosphoryla-
tion of MKK4 (Fig. 5). In two of the three clones analyzed,
high concentrations of anti-CD3 mAb induced phosphory-
lation of MKK4. This phosphorylation was decreased or
absent when the cells were stimulated with suboptimal
doses of anti-CD3 mAb. All of the clones, when stimulated
with anti-CD158b/j mAb alone or in combination with
suboptimal anti-CD3 mAb, induced phosphorylation of
MKK4. This confirmed the initial findings that stimulation
Figure 3. Stimulation through CD158b/j results in an up-regulation of
ATF-2 and HSP27 transcripts. The PathwayFinder cDNA Array is spotted
in duplicate with 23 cDNAs. Represented on the membrane are the
ERK (egr-1 and c-fos), JNK (ATF-2, hsf1, HSP27, and HSP90), NF- B
(iNos, NF- B, and I B ), NFAT (IL-2, Fas, and CD5), TGF-  (p16,
p21, and p57Kip2), Wnt (c-myc), p53 (p21, gadd45, pig7, pig8, mdm2,
and bax), and CREB pathways (egr-1, CYP19, and c-fos). The mem-
brane also included a negative control (pUC18) and two positive controls
( -actin and GAPDH) (A). A CD4 CD28nullCD158b/j  T cell clone
was stimulated with control mouse IgG or anti-CD158j mAb and cross-
linked with rabbit anti–mouse IgG Ab. Total RNA was harvested and
used to probe the PathwayFinder cDNA Array (B).
Figure 4. Stimulation of CD158b/j in CD4 CD28null T cells leads to
JNK, but not ERK, phosphorylation. CD4 CD28nullCD158j  T cell
clones shown in Figure 1 (clones #1, #2, and #4) were stimulated with
anti-CD3 and/or anti-CD158b/j mAbs and cross-linked with rabbit anti–
mouse IgG Ab. After SDS-PAGE and transfer to a nitrocellulose mem-
brane, the cell lysates were analyzed for phosphorylation of JNK (left pan-
els), after which the blots were stripped and reprobed with Abs against
total JNK (right panels) (A). After SDS-PAGE and transfer to a nitrocel-
lulose membrane, the cell lysates were analyzed for phosphorylation of
ERK (left panels), after which the blots were stripped and re-probed with
Abs against total ERK (right panels) (B).T
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through CD158b/j activates the JNK pathway in
CD4 CD28null T cells.
CD158j, and Not CD158b, Induces Activation of the JNK
Pathway. As previously stated, the mAb used to stimu-
late CD158b/j recognizes three related gene products,
CD158b1/b2 and CD158j. CD4 CD28nullCD158b/j  T
cell clones used so far for the signaling studies expressed
transcript for both CD158b1 and CD158j. CD158b1 is
known to activate protein phosphatases and to inhibit other
activating receptors. However, it has also been demon-
strated to bind to and activate phosphatidylinositol 3-kinase
(PI3K; reference 22). To experimentally address the ques-
tion of which receptor, CD158j or CD158b1, activates
the JNK pathway, we identified three CD4 CD28null
DAP12null T cell clones, two of which only expressed
CD158j and the other of which expressed only CD158b1.
For the two CD158j  clones, stimulation through either
the TCR or CD158j resulted in phosphorylation of JNK
(Fig. 6 A, top panels). In contrast, in the CD158b1  clone,
only stimulation through the TCR activated the JNK path-
way (Fig. 6 A, bottom panel). To confirm that CD158j was
specifically responsible for the activation of this pathway in
CD4 CD28null T cells, we infected Jurkat T cells with re-
combinant vaccinia virus containing the CD158j cDNA.
This allowed for the expression of CD158j in the absence
of any other receptors recognized by the GL183 mAb. Af-
ter infection, the expression of CD158j was confirmed by
flow cytometry (Fig. 6 B). Prior to infection or after infec-
tion with wild-type vaccinia virus, the Jurkat T cells did
not express any receptors recognized by the anti-CD158b/
j mAb. However, after infection with vaccinia virus con-
taining the cDNA for CD158j, essentially all of the cells
expressed CD158j at levels equivalent to the endogenous
expression observed on CD4 CD28null T cells. Infected
Jurkat T cells were stimulated with a control mAb, anti-
CD3 mAb, anti-CD158b/j mAb, or a combination of anti-
CD3 and anti-CD158b/j mAbs and then analyzed for JNK
phosphorylation (Fig. 6 C). Although anti-CD3 mAb
induced limited phosphorylation of JNK, stimulation
through CD158j activated the signaling cascade that re-
sulted in significant JNK phosphorylation. This activation
after CD158j stimulation was not observed in Jurkat cells
infected with wild-type virus. In addition, stimulation
through CD158j also induced MKK4 phosphorylation in
Figure 5. Stimulation of CD158b/j in CD4 CD28null T cells leads to
MKK4 phosphorylation. CD4 CD28nullCD158j  T cell clones (clones
#1, #2, and #4) were stimulated with anti-CD3 and/or anti-CD158b/j
mAbs and cross-linked with rabbit anti–mouse IgG Ab. After SDS-PAGE
and transfer to a nitrocellulose membrane, the cell lysates were analyzed
for phosphorylation of MKK4 (left panels). The blots were stripped and
reprobed with Ab against total MKK4 (right panels).
Figure 6. Phosphorylation of JNK is initiated by stimulation specifically
through CD158j. Two CD4 CD28nullCD158j  T cell clones (top panels)
and a CD4 CD28nullCD158b1  T cell clone (bottom panels) were stimu-
lated with anti-CD3 and/or anti-CD158b/j mAbs and cross-linked with
rabbit anti–mouse IgG Ab. After SDS-PAGE and transfer to a nitrocellulose
membrane, the cell lysates were analyzed for phosphorylation of JNK (left
panels). The blots were then stripped and reprobed with Abs against total
JNK (right panels; A). Jurkat T cells were infected with either wild-type vac-
cinia virus (WR) or vaccinia virus containing CD158j cDNA and were ana-
lyzed for expression of CD158j by flow cytometry (B). Jurkat T cells infected
with WR vaccinia virus or CD158j  vaccinia virus were stimulated with
anti-CD3 and/or anti-CD158b/j mAbs and cross-linked with rabbit anti–
mouse IgG Ab. After SDS-PAGE and transfer to a nitrocellulose membrane,
the cell lysates were analyzed for phosphorylation of JNK (top left panels)
and MKK4 (bottom left panel). The blots were stripped and reprobed with
Abs against  -actin (top right panels) or MKK4 (bottom right panel) (C).T
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transfected CD158j  Jurkats (Fig. 6 C). These results con-
firmed that, in the CD4 CD28nullCD158b/j  T cells,
CD158j is responsible for the activation of the JNK signal-
ing pathway. They also demonstrate that the CD158j-
mediated JNK activation is not limited to CD4 CD28null T
cells but principally is possible in other KARAP/DAP12-
negative CD4  T cells.
Activation of CD158j Leads to Expression of ATF-2 and
c-Jun. Activation of the JNK signaling pathway leads to the
phosphorylation and activation of specific transcription fac-
tors, including ATF-2 and c-Jun (20, 21). These two tran-
scription factors form a heterodimer and bind to modified
AP-1 sites, one of which is located within the promoter re-
gion of the IFN-  gene (23). Stimulation through CD158j
in CD4 CD28null T cells led to increased IFN-  expression
(Fig. 2), possibly mediated through JNK-induced activation
of ATF-2 and c-Jun. For all CD4 CD28nullCD158b/j  T
cell clones tested, we observed that stimulation through ei-
ther the TCR or CD158j led to phosphorylation of both
ATF-2 and c-Jun (data not shown). In addition to regulat-
ing the expression of IFN- , activation of the JNK path-
way leads to increased expression of c-Jun (20, 21). As in-
dicated by the PathwayFinder cDNA Array, transcription
of the ATF-2 gene is also regulated by the JNK pathway.
To determine whether CD158j stimulation regulates the
expression of these transcription factors, CD4 CD28null
CD158b/j  T cells and Jurkat T cells infected with
CD158j  vaccinia virus were stimulated and then analyzed
for expression of ATF-2 and c-Jun (Fig. 7). In two of the
clones, stimulation with optimal, but not suboptimal, con-
centrations of anti-CD3 mAb led to increased expression of
both ATF-2 and c-Jun. In the remaining clone, clone #4
and in the vaccinia virus-infected Jurkat T cells, stimulation
through the TCR did not induce the expression of either
transcription factor. This is consistent with the failure of
anti-CD3 to induce MKK4 and JNK phosphorylation in
these cells (Figs. 4 A, 5, and 6). In contrast, for each of the
clones analyzed, stimulation through CD158j alone or in
combination with low-dose anti-CD3 mAb resulted in ex-
pression of both c-Jun and ATF-2. This was also observed
for Jurkat T cells induced to express CD158j after infection
with vaccinia virus. This suggests that CD158j, in conjunc-
tion with the TCR, costimulates IFN-  production in
CD4 CD28null T cells through the expression and activa-
tion of ATF-2 and c-Jun after induction of the JNK signal-
ing pathway.
The Adaptor Binding Motif in the Transmembrane Region Is
Required for CD158j Function. All known stimulatory
members of the KIR family possess a dramatically short-
ened cytoplasmic tail in comparison with the inhibitory re-
ceptors and a positively charged residue within the trans-
membrane domain. The cytoplasmic domains of these
receptors are not capable of directly initiating signaling
events and must rely on adaptor molecules, such as
KARAP/DAP12. Because each of the known adaptor
molecules contains a negatively charged residue in their
transmembrane domains, it is hypothesized that the interac-
tion between a stimulatory receptor and its corresponding
adaptor molecule is partially modulated through an electro-
static interaction. We have demonstrated that in CD4 
CD28null T cells, CD158j is capable of activating the JNK
signaling pathway and IFN-  expression in the absence of
KARAP/DAP12. To explore whether CD158j is using an
alternate adaptor molecule to activate the JNK pathway
that also interacts through the lysine residue within the
transmembrane domain, we constructed a mutant of
CD158j in which this lysine residue was changed to a hy-
drophobic residue (CD158jK233I). After transfection into
Jurkat T cells, both CD158j and CD158jK233I were ex-
pressed on the cell surface (Fig. 8 A) at similar levels. Al-
though stimulation through CD158j resulted in phosphor-
ylation of JNK, stimulation through CD158jK233I did not
(Fig. 8 B). This suggests that mutation of the transmem-
brane lysine residue disrupted the interaction between the
receptor and its unknown adaptor molecule, preventing ac-
tivation of the JNK signaling pathway.
Lack of Association between DAP10 and CD158j. As
previously stated, stimulatory receptors within the KIR
family require an adaptor molecule to activate signaling
cascades. Stimulatory receptors from other families, such as
the C-type lectin family, also display this requirement.
Some adaptor molecules, such as the common FcR  chain
and KARAP/DAP12, associate with a number of different
receptors (24). We hypothesized that, in CD4 CD28null T
cells, CD158j is associating with another known adaptor
molecule previously characterized for its interaction with a
different stimulatory receptor. One such candidate mole-
cule is DAP10. DAP10 associates with NKG2D and is
found in most NK cells and CD8  T cells. Whereas
KARAP/DAP12 contains ITAMs and activates the ty-
rosine kinases Syk and ZAP-70, DAP10 contains PI3K
binding domains within its cytoplasmic domain. This made
it a potential candidate for association with CD158j in
CD4 CD28null T cells because PI3K is capable of activat-
ing the JNK pathway. In addition, although NKG2D can
induce cytotoxicity in NK cells, it functions solely as a
costimulatory receptor in CD8  T cells (25). This is simi-
lar to the functional activity displayed by CD158j in
Figure 7. Stimulation of CD158j in CD4 CD28null T cells leads to ex-
pression of ATF-2 and c-Jun. CD4 CD28nullCD158j  T cell clones
(clones #2, #3, #4), and Jurkat T cells expressing CD158j were stimu-
lated with anti-CD3 and/or anti-CD158b/j mAbs and cross-linked with
rabbit anti–mouse IgG Ab. After SDS-PAGE and transfer to a nitrocellu-
lose membrane, the cell lysates were analyzed for expression of ATF-2
and c-Jun. The membranes were stripped and reprobed with Ab against
 -actin.T
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CD4 CD28null T cells. We analyzed several CD4 
CD28null T cell clones and found expression of DAP10
transcript (Fig. 9 A). If CD158j is signaling through DAP10
and PI3K, blocking experiments with the PI3K inhibitor
wortmannin should inhibit JNK activation induced by
CD158j. CD4 CD28nullCD158j  T cell clones were stim-
ulated with anti-CD3 or anti-CD158j mAb in the presence
or absence of wortmannin, and were then analyzed for
JNK phosphorylation (Fig. 9 B). Although wortmannin
had a limited inhibitory effect on TCR-mediated JNK
phosphorylation, it led to significant inhibition of JNK ac-
tivation mediated by CD158j.
CD158j/DAP10 association was difficult to study in T
cell clones because of the high cell numbers required. To
determine if DAP10 associates with CD158j, we used RBL
cells, which expressed endogenous DAP10 but not
KARAP/DAP12, and which had been stably transfected
with CD158j. As indicated by flow cytometry, CD158j
was expressed on the cell surface of RBL cells despite the
lack of KARAP/DAP12 (Fig. 9 C, top panel). In
CD158jnull RBL cells, DAP10 coimmunoprecipitated with
a protein of  50 kD, the identity of which was unclear. In
CD158j  RBL cells, the immunoprecipitation pattern was
essentially unchanged (Fig. 9 C, bottom panel). Coimmu-
noprecipitation of KARAP/DAP12 and CD158j from
KARAP/DAP12 CD158j  RBL cells was included as a
control. The apparent molecular weight of CD158j is  50
kD. However, even if CD158j was included in this 50-kD
band the amount would be minuscule. In support of this
interpretation, CD158j did not function as a costimulatory
Figure 8. Mutation of transmembrane lysine residue in CD158j abol-
ishes ability to induce JNK phosphorylation. Jurkat T cells were tran-
siently transfected with constructs containing the CD158j cDNA or the
CD158j233I cDNA. Cell-surface expression was confirmed by flow
cytometry (A). Jurkat T cells transfected with either CD158j or
CD158jK233I were stimulated with anti-CD3 or anti-CD158b/j mAb
and cross-linked with rabbit anti–mouse IgG Ab. After SDS-PAGE and
transfer to a nitrocellulose membrane, the cell lysates were analyzed for
phosphorylation of JNK (left panels). The blots were then stripped and
reprobed with Abs against total JNK (right panels) (B).
Figure 9. CD158j and DAP10 do not associate. RT-PCR was used to
amplify transcripts for DAP10 from PBMCs (lane 1) and CD4 CD28null T
cell clones (lanes 2–5). cDNA was omitted for the negative control (lane 6)
(A). CD4 CD28nullCD158b/j  T cell clones were stimulated with anti-
CD3 or anti-CD158b/j in the presence or absence of 2.0  M wortmannin.
After SDS-PAGE and transfer to a nitrocellulose membrane, the cell lysates
were analyzed for phosphorylation of JNK (left panels). The blots were then
stripped and reprobed with Abs against  -actin (right panels). Results from
two T cell clones are shown (B). DAP10-expressing RBL cells (left panel)
were stably transfected with CD158j alone (middle panel) or with CD158j
and KARAP/DAP12 (right panel). Cell surface expression of CD158j was
confirmed by flow cytometry (top panels). DAP10 or KARAP/DAP12 was
immunoprecipitated from lysates of biotinylated transfected RBL cells. After
SDS-PAGE and transfer to nitrocellulose membranes, coimmunoprecipi-
tated cell-surface proteins were detected by streptavidin-HRP (middle pan-
els). Immunoprecipitation of DAP10 and KARAP/DAP12 was confirmed
by immunoblot with anti-DAP10 or anti-KARAP/DAP12 Ab (bottom
panels) (C). DAP10 or KARAP/DAP12 was immunoprecipitated from Jur-
kat T cells (lanes 1–3) or RBL cells (lanes 4–6). After SDS-PAGE and trans-
fer to a nitrocellulose membrane, samples (protein-G preclear, lanes 1 and 4;
DAP10 immunoprecipitate, lanes 2 and 5; KARAP/DAP12 immunopre-
cipitate, lanes 3 and 6) were analyzed by Western blot using DAP10 Ab (D).
molecule in RBL cells (unpublished data). Moreover,
DAP10 appeared not to be involved in the CD158j in-
duced activation of the JNK pathway in Jurkat T cells. InT
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these experiments, DAP10 was immunoprecipitated from
Jurkat T cells and RBL cells, then analyzed through a
Western blot with a DAP10 antibody (Fig. 9 D). Com-
pared with the RBL cells, miniscule amounts of DAP10
were present in Jurkat T cells that could only be detected
after overexposure of the Western blot. Thus, despite the
detection of DAP10 transcript and inhibition of JNK acti-
vation with wortmannin, our immunoprecipitation data do
not support the hypothesis that DAP10 is functioning as
the adaptor molecule for CD158j in CD4 CD28null T
cells.
Discussion
The results presented here demonstrate that stimulation
of the MHC class I–recognizing receptor, CD158j, acti-
vates the JNK signaling pathway in CD4  T cells. The ac-
tivation of this pathway is independent of the adaptor mol-
ecule, KARAP/DAP12, which usually associates with
CD158j (7, 8). Activation of the JNK pathway by CD158j
led to increased expression and phosphorylation of the
transcription factors ATF-2 and c-Jun, which regulate the
expression of IFN-  (23). Indeed, triggering of CD158j
provided costimulatory signals for IFN-  production by
the responding CD4  T cell population.
We and others have reported that CD158b/j and other
MHC class I–recognizing receptors are expressed on a
small subset of CD4  T cells that shows evidence of an ex-
tensive replicative history (10, 26, 27). These T cells have
many characteristics of NK-T cells. They express perforin
and granzyme B and they have lost the costimulatory mol-
ecule, CD28; however, they do not express the canonical
TCR structure typically seen on NK-T cells (28). Mandel-
boim and colleagues (26) were the first to demonstrate that
stimulatory MHC class I–recognizing receptors provided
costimulatory signals in this subtype of T cells. They
showed that these receptors acted as costimulatory mole-
cules for superantigen-induced T cell proliferation. Expres-
sion of CD158j and its proposed ligand, HLA-C, are con-
stitutive and are not under regulatory control, in contrast to
most costimulatory receptors and ligands. The authors,
therefore, proposed that CD158j expression and signaling
may be important in breeches of tolerance, leading to au-
toimmunity. In support of this model, we demonstrated
that CD158j is frequently expressed on CD4  T cells in
patients with RA, particularly those who have developed
vascular complications (13, 15). We also confirmed that
CD158j provides costimulatory signals for proliferation
(27). However, in contrast to CD158j on NK cells,
CD158j on cytotoxic CD4  T cells did not induce or aug-
ment a cytotoxic T cell response, raising the possibility that
the signaling pathways of stimulatory KIRs in T cells and
NK cells are different.
CD158j does not possess a substantial cytoplasmic do-
main. As a result, it is dependent on an adaptor molecule to
initiate signaling events. In NK cells, this adaptor molecule
is KARAP/DAP12. KARAP/DAP12 has a cytoplasmic
ITAM motif and is able to recruit and activate Syk and
ZAP-70 (8, 29, 30). Activation of these tyrosine kinases in-
duces ERK activation via the Raf/Mek/ERK cascade (31).
It also activates PLC- 1, leading to intracellular calcium
flux. Strikingly, the vast majority of CD4  T cells, includ-
ing the CD4 CD28null T cell clones characterized in this
paper, do not express KARAP/DAP12 even in the pres-
ence of cell-surface CD158j. This would explain why
CD158j does not induce any calcium flux and cannot in-
duce cytotoxic activity in CD4 CD28null T cells (27). We
also have isolated CD4 T cell clones that express KARAP/
DAP12 and CD158j triggering of these T cell clones in-
duces cytotoxicity. Specifically, we have found an in-
creased frequency of KARAP/DAP12 expression in CD4 
CD28null T cells from patients with ACS (32). Such clones
are highly infrequent in healthy controls and it is currently
unknown how frequent these cells are in patients with RA.
However, the majority of CD4  T cells in RA are clearly
KARAP/DAP12 negative. CD158j stimulation activates
the JNK pathway and costimulates IFN-  expression in
CD4 CD28null T cells that do not express this adaptor
molecule regardless of whether they are derived from RA
patients or other sources. These data show that CD158j has
as yet undescribed functions in T cells that are distinct from
the CD158j/KARAP/DAP12/Syk pathway described in
NK cells.
Our mutational analysis demonstrated that the activa-
tion of the JNK pathway by CD158j is dependent on a
charged residue in the transmembrane domain, suggesting
that an adaptor molecule is involved. Certain stimulatory
receptors, specifically NKG2D, can bind to and signal
through both KARAP/DAP12 and another adaptor mole-
cule DAP10 (33–36). Other receptors related to the stim-
ulatory KIRs, including immunoglobulin-like transcript-1
(ILT-1) and paired-immunoglobulin receptor-A (PIR-A),
can also signal through other adaptor molecules that share
with KARAP/DAP12 the presence of a negatively
charged residue within the transmembrane domain (37,
38). These molecules include the   chain of the Fc recep-
tor (FcR ) and the CD3   chain. Although both ILT-1
and PIR-A interact with FcR , CD158j does not. CD3  
is certainly a potential adaptor molecule because it is ex-
pressed in all T cells; however, as is the case with FcR ,
CD3   is unable to interact with CD158j (39). Even if
CD3   or FcR  were capable of binding to CD158j, their
signaling properties would not be expected to induce a
preferential activation of the JNK pathway. Both of these
molecules signal through multiple pathways, including
ERK and PLC- ; however, neither of these is activated
after CD158j stimulation, suggesting that CD158j binds to
an unidentified adaptor molecule that leads to the activa-
tion of the JNK pathway.
We focused on DAP10 as a possible adaptor molecule
for CD158j in CD4 CD28null T cells for several reasons.
First, the level of sequence homology that exists between
KARAP/DAP12 and DAP10 suggests that they may be ca-
pable of substituting for one another with regards to recep-
tor association (40). Second, PI3K, which is activated by
DAP10, can induce JNK phosphorylation through the in-T
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termediate, Vav1. This would correlate with our data dem-
onstrating that activation of the JNK pathway by CD158j
in CD4 CD28null T cells can be inhibited by wortmannin.
Third, initial experiments indicated that DAP10 is ex-
pressed in CD4 CD28null T cell clones. Experiments were
undertaken in an attempt to demonstrate a physical associa-
tion between CD158j and DAP10. However, these exper-
iments failed to show any such association. In addition,
CD158j is capable of inducing JNK phosphorylation in
Jurkat T cells, which express only limited amounts of
DAP10. In summary, our data do not support the hypothe-
sis that DAP10 serves as the adaptor molecule for CD158j
in CD4 CD28null T cells. This is in agreement with previ-
ously published reports that also failed to demonstrate any
interaction between CD158j and DAP10 (39).
Activation of the JNK pathway has been postulated to be
a hallmark of costimulatory signals. CD28 is the principal
costimulatory molecule in CD4  T cells and predomi-
nantly facilitates the production of IL-2. Several down-
stream events of CD28 signaling have been described (41,
42). Although controversial, there are several lines of ex-
perimental evidence that suggest activation of the JNK
pathway is central to CD28 responses (43–45). JNK-
induced phosphorylation is critical in the activation of
c-Jun, a component of the transcription factor AP-1,
which is known to bind to the IL-2 promoter as well as to
the IFN-  promoter (23, 46, 47). Activation of the JNK
pathway in Jurkat T cells requires cotriggering of CD3 and
CD28 (48). Furthermore, JNK activation is blunted in an-
ergic Th1 clones (49).
It is interesting to note that costimulatory signals that
can, in part, substitute for CD28 have also been shown to
signal through the JNK pathway. Ligand engagement of
the 4–1BB (CD137) molecule, which is expressed on acti-
vated T cells, costimulates IL-2 production and prolifera-
tion independent of CD28 ligation (50). CD137 signals
through TRAF2, which leads to the downstream activation
of the JNK pathway (47). Ox-40 (CD134), also a costimu-
latory molecule selectively expressed on activated T cells,
associates with TRAF2 and probably also activates the JNK
pathway (51, 52). Cannons and colleagues (50) found evi-
dence for the hypothesis that activation of the JNK path-
way by other inducers of stress-activated kinases, such as
hyperosmotic shock, provides costimulatory signals to T
cells. It is, therefore, of particular interest that CD158j trig-
gering in T cells, in the absence of KARAP/DAP12, selec-
tively targets the activation of the JNK pathway.
The receptors CD158b1, CD158b2, and CD158j share
virtually identical extracellular domains. As a result, it was
hypothesized that each would recognize the same ligand,
specifically HLA-C. The inhibitory receptors CD158b1/b2
clearly recognize specific alleles of HLA-C. Target cells ex-
pressing HLA-Cw1, 3, 7, or 8 are protected from lysis by
CD158b1/b2  NK cells. In addition, in vitro experiments
demonstrate direct binding between CD158b1/b2 and ap-
propriate HLA-C alleles (1, 53). However, despite the high
degree of sequence similarity between the extracellular do-
mains of the inhibitory and stimulatory receptors, no bind-
ing between soluble CD158j and HLA-C has been demon-
strated. This lack of interaction is attributed to the
sequence difference between CD158j and CD158b1/b2 at
position 45. In CD158b1/b2, the residue at this position is
a phenylalanine while in CD158j, the residue is a tyrosine.
Mutation of this residue in CD158j to phenylalanine par-
tially restored the interaction with HLA-C, indicating the
importance of this residue (1). Currently, the identity of
the ligand for CD158j is unconfirmed. It is possible that, in
vivo, CD158j is capable of interacting with particular
HLA-C molecules. The interaction between CD158b1/b2
and HLA-C is dependent on the sequence of the peptide
bound to the class I molecule (1, 54), which may also be
the case for CD158j. Further experimentation is required
before the in vivo ligand for CD158j can be confirmed.
Unopposed costimulatory function could occur if
CD158j is expressed in the absence of any inhibitory re-
ceptors. In this context, it is of interest that CD4 CD28null
T cells that express members of the KIR family usually do
not express CD94 or any inhibitory members of the
C-type lectin receptors (27). Moreover, we (55) and others
have demonstrated that KIR expression is acquired during
clonal expansion of T cells (56, 57). T cells expressing
identical TCRs express different repertoires of KIRs,
clearly indicating that KIR expression is initiated after
TCR rearrangement. Because KIR expression appears to
be a stochastic event, it can be envisioned that T cell clones
are generated that express stimulatory KIRs in the absence
of inhibitory receptors. Indeed, we have shown that this is
the case in patients with RA. Patients with RA frequently
possess expanded populations of CD4 CD28null T cells that
express various members of the KIR family. This popula-
tion of CD4 CD28null T cells results from the expansion of
a limited number of autoreactive clones (12, 58). CD158j
is most frequently expressed, often in the absence of
CD158b1/b2 (27). Genotyping studies have shown that
the CD158j gene is a risk factor for extraarticular manifes-
tations of RA, such as rheumatoid vasculitis (15). Because
CD158j costimulates proliferation, this receptor may play a
role in the expansion of these autoreactive T cells. In addi-
tion, CD158j may also be an important regulatory mole-
cule for effector functions. It has been shown that the JNK
pathway is most important for regulating T cell effector
function and not T cell activation (59). The activation of
CD158j, in conjunction with TCR, leads to production of
the inflammatory cytokine, IFN- . Coactivation of the
JNK pathway by CD158j, therefore, regulates several im-
portant cell functions as a costimulatory molecule. Expres-
sion of CD158j on T cells may essentially undermine toler-
ance and amplify autoimmune mechanisms.
In summary, we have demonstrated that CD158j, de-
pending upon its coupling to adaptor molecules, can have
various functions. Whereas CD158j in association with
KARAP/DAP12 acts as a primary recognition structure in
NK cells, CD158j, presumably associated with an as of yet
unidentified adaptor molecule, functions as a costimulatory
complex in concert with the TCR in KARAP/DAP12null
T cells. This CD28-independent costimulatory activity isT
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mediated through the JNK signaling pathway. The activa-
tion of the JNK pathway has important implications for the
stimulatory activity of CD158j. We hypothesize that this
could have dramatic effects on the function of the
CD4 CD28null T cells that express CD158j and on their
pathogenic role in autoimmunity.
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